Recent Patents Applications in Red Biotechnology: A Mini-Review

Author(s): Raíssa C.D. Graciano, Júlia A.T. Ribeiro, Anderson K.S. Macêdo, José Paulo de S. Lavareda, Pedro R. de Oliveira, Jairo B. Netto, Laís M. Nogueira, Juliana M. Machado, Mariana Camposda-Paz, Rodolfo C. Giunchetti, Alexsandro S. Galdino*.

Journal Name: Recent Patents on Biotechnology

Volume 13 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The different fields of biotechnology can be classified by colors, as a "rainbow" methodology. In this sense, the red biotechnology, focused on the preservation of health, has been outstanding in helping to solve this challenge through the provision of technologies, including diagnostic kits, molecular diagnostics, vaccines, innovations in cancer research, therapeutic antibodies and stem cells.

Objective: The main goal of this work is to highlight the different areas within the red Biotechnology. In this sense, we revised some patents regarding red biotechnology as examples to cover this subject.

Methods: A literature search of patents was performed from the followings Patents Database: INPI, USPTO, Esp@cenet, WIPO and Google Patents.

Results: Our analysis showed the following numbers from patents found: cancer research (8), diagnosis kit (9), vaccines (8), stem cells (9) and therapeutic antibodies (5), where the United States is the leader for most filled patents in Red Biotechnology.

Conclusion: This mini-review has provided an update of some patents on Recent Patents in Red Biotechnology. As far as we know, this is the first mini-review report on Red Biotechnology based on patents.

Keywords: Red Biotechnology, diagnosis kit, vaccines, stem cells, cancer, therapeutic antibodies.

[1]
Oecd, Organisation For Economic Co-Operation and Development. A Framework for Biotechnology Statistics. OECD Publishing. 2005; Available from.www.oecd.org/sti/sci-tech/34935605.pdf [cited: 13th Aug 2018].
[2]
DaSilva EJ. The Colours of Biotechnology: Science, Development and Humankind. Electron J Biotechnol 2004; 7(3): 1-2.
[3]
De La Vega I, Requena J, Fernández-Gómez R. The colors of biotechnology in Venezuela: a bibliometric analysis. Technol Soc 2015; 42: 123-34.
[4]
Afzal H, Zahid K, Ali Q, et al. Role of Biotechnology in Improving Human Health. J Mol Biomark Diagn 2016; 7(6): 1-7.
[5]
Kafarski P. Rainbow code of biotechnology. Chemik 2012; 66(8): 814-6.
[6]
Kircher M. White biotechnology: ready to partner and invest in. Biotechnol J 2006; 1: 787-94.
[7]
Streltsova E, Linton JD. Biotechnology patenting in the BRICS countries: strategies and dynamics. Trends Biotechnol 2018; 36(7): 642-5.
[8]
Google patent. Available from. https://patents.google.com [cited: 2th Mar 2018].
[9]
USPTO. The United States Patent and Trademark Office. Available from. https://www.uspto.gov/about-us [cited: 31th Mar 2018]
[10]
Espacenet. Available from. https://www.epo.org/ aboutus/office.html [cited: 21th Apr 2018].
[11]
Patentscope. Available from. http://www.wipo.int/ patentscope/en/ [cited: 1th May 2018].
[12]
National Institute of Industrial Property (INPI). Available from. http://www.inpi.gov.br/Portal/ sobre/estrutura [cited: 1th Apr 2018].
[13]
Santos MO. Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro: INCA (Instituto Nacional de Câncer José Alencar Gomes da Silva) 2017.
[14]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359-86.
[15]
Athayde Filho PF, Barbosa Filho JM, Lira BF. Pharmaceutical analogues of piperine for the treatment of cancer. BR 102016019918-2 A2. 2016.
[16]
Garzioni PP, Guimarães RC, Guimarães JLCA. Pharmaceutical compounds for the treatment of cancer. BR1020170136930A2. 2017.
[17]
Chandrasekhar J, Patel L, Perreault S, et al. A compound, a pharmaceutically acceptable salt, isomer or a mixture thereof, pharmaceutical composition, method for treatment of a disease or condition, inhibition of the activity of a polypeptide phosphatidylinositol 3- kinase and inhibition of excessive or destructive immune reactions or growth or proliferation of cancer cells, kit, and, use of a compound, a pharmaceutically acceptable salt, isomer or a mixture thereof. BR102017 0194477A2, 2017.
[18]
Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999; 274(13): 8347-50.
[19]
Yíngchūn H, Yù W. kūn Z, Téng M, Qí W. Application of miRNA-6126 as diagnostic marker of lung cancer. CN106929599A, 2017.
[20]
Luánlìbiāo, Siyuan H. 3-O-(para-methanesulfonate benzyl)-ascorbic acid with anticancer activity and preparation method. CN107056733A. 2017.
[21]
Changhao C, Fanlin L, Li W, et al. Application of apoptosis-inducing reagent in human breast cancer cell . CN107260753A, 2017.
[22]
Huang C, Tzeng YM, Yeh CT, Wu THA. Method for inhibiting growth of ovarian cancer cells. US20180050012A1, 2017.
[23]
SokoloV PM, Sukhanova A, Nabiyev IR. Method for directed destruction of cancer cells. RU2638446C1. 2016.
[24]
Self CH, Cook DB. Advances in immunoassay technology. Curr Opin Biotechnol 1996; 7(1): 60-5.
[25]
World Health Organization. HIV Assays: operational Characteristics. Repot 15, 2005. Available from. www.who.int/diagnostics_laboratory/publications/en/HIV_Report15.pdf [cited: 25th Apr 2018].
[26]
Shanrong L, Shuqun C, Kai C, et al. One kind opn, gdf15, nse, trap5 e opg joint diagnostic kit. CN107462720A. 2017.
[27]
Hao Z. Application of mirna in preparation of cancer diagnostic kit. CN106834470A. 2017.
[28]
Lianwen Q, Yong F, Ping L, Wei Z, Yan C. Stable angel differentiation method of acute coronary syndrome and the diagnostic kit of the same. US2018088132A1. 2018.
[29]
Hyun KJ, Soo J, Hoon S, Ki B, Jung JJ. Composition of detecting biomarker for diagnosis degree of obesity rapid diagnostic kit using the same and method for diagnosis using the same. KR20180032830. 2018.
[30]
Faculdade de Medicina da UFBA. Introdução ao Imunodiagnóstico, Available from. www.medicina. ufba.br/imuno/roteiros_imuno/Introd%20Imunodiag-nostico.pdf [cited: 30 th Apr 2018].
[31]
Hak CJ, Jin LW, Keun LS. Hiv 1,2,0 simultaneous diagnosis kit for hiv type 1, 2 and 0 using immunochromatographic assay and simultaneous diagnosis method using the same. KR20180025830. 2018.
[32]
Aniz PAEA, Gotti TB, Piazza RMF, Rocha LB. A method, device and kit for in vitro immunochromatographic diagnosis of leptospirosis and / or for detection of leptospiraspp infection; process for its preparation. BR1020160206170A2. 2018.
[33]
Myung SS. Kit for detecting intestinal parasites and detection method using the same. KR20180008836A. 2018.
[34]
Freire ML. Avaliação de desempenho e custos diretos de kits comercialmentedisponíveis no Brasil e do protótipo DAT-LPC para o diagnóstico da leishmaniose visceral humana Dissertação Belo Horizonte Fundação Oswaldo Cruz - Instituto René Rachou 2017.
[35]
Dias DS, Ribeiro PAF, Nogueira LM, Silva ES, Gal-dino AS. Recombinant multiepitope protein, its process of production and its applications related to Leishmaniasis. BR1020140313311. 2014.
[36]
Dias DS, Ribeiro PAF, Nogueira LM, et al. Recombinant multiepitope protein and its use for the diagnosis and treatment of Leishmaniasis. BR1020150161620. 2015.
[37]
Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine 2014; 32: 2150-9.
[38]
Cunningham AL, Garçon N, Leo O, et al. Vaccine development: From concept to early clinical testing. Vaccine 2016; 34: 6655-64.
[39]
Kaech SM, Wherry EJ, Ahmed R. Vaccines: effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2: 251-62.
[40]
Serruto D, Adu-Bobie J, Capecchi B, Rappuoli R, Pizza M, Masignani V. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J Biotechnol 2004; 113: 15-32.
[41]
Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013; 8: 360-76.
[42]
Moyle PM. Progress in vaccine development. Curr Protoc Microbiol 2015; 36: 18-1.
[43]
Del Giudice G, Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 1999; 17: 44-S52.
[44]
Ciaramella G. Ebola vaccine. WO2017015457A1. 2017.
[45]
Towner JS, Nichol ST, Comer JA, Ksiazek TG, Rollin PE. Human ebola virus species and compositions and methods thereof. US20180002675A1. 2018.
[46]
Ciaramella G, John S, Bett AJ, Casimiro DR. Herpes simplex virus vaccine. WO2017070623A1, 2017.
[47]
Ciaramella G, Huang EY, Babaoglu K, Flynn JA, Zhang L. Broad spectrum influenza virus vaccine. WO2017070620, 2017.
[48]
Solodushko VG, Fouty B, Bitko V. Novel platform dna vaccine. WO2017079625A1, 2017.
[49]
Chacornac I, Francon A, Vacus P. Vaccine composition comprising ipv and cyclodextrins. WO20160123 85A1, 2016.
[50]
Giunchetti RC, Alves MLR, Dutra WO, et al. Vaccinal composition containing crude extract of mosquito intestinal proteins and obtaining process. BR1020170278859, 2017.
[51]
Giunchetti RC, Leite JC, Silveira P. Peptide, vaccine for flebotomyne control and uses. BR1020170 229068, 2017.
[52]
Pereira LV. A importância do uso das células-tronco para a saúde pública. Cien Saude Colet 2008; 13: 7-14.
[53]
Rose N. The politics of life itself: biomedicine, power and subjectivity in the twenty-first century 1 ed Oxford: Princeton University Press 2006.
[54]
Zorzanelli RT, Speroni AV, Menezes RA, Leibing A. Stem cell research in Brazil: the production of a new field of Science. Hist Cienc Saude Manguinhos 2017; 24: 129-44.
[55]
Brotas CLC. Stem cell patents: a bioethical look. Rev Brasil Dir Anim 2014; 01: 219-75.
[56]
Aharonowiz M, Einstein O, Reubinoff B, Ben-Hur T. Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system. US20180322. 2018.
[57]
Sun X, Lim B. Generation of functional cells from stem cells. US20180072988, 2018.
[58]
Roux P. Reprogramming Method for producing induced pluripotent stem cells (iPSC). US20180023056, 2018.
[59]
Ikeyama Y, Okubo T, Nishida H, Tsuda T, Uno E, Yumoto M. Mesenchymal stem cell culture medium, methods for culturing mesenchymal stem cells, and mesenchymal stem cells. US20180066231, 2018.
[60]
Tremolada C, Ventura C, Graves M. Method and device for preparing non-embryonic stem cells. US20180066232, 2018.
[61]
Eto K, Endo H, Shigemori T. Method for producing stem cell clones suitable for induction of differentiation into somatic cells. US20180051260, 2018.
[62]
Wang J, Chen SK, Lin MS, Yen Y. Method for increasing number of stem cells in human or animal bodies. US20180024122, 2018.
[63]
Bos CVD, Reinisch B, Schenk J, Rosenbaum C. Compositions and methods for enhancing the therapeutic potential of stem cells. US20180055888, 2018.
[64]
Giunchetti RC, Orefice RL, Lima TH, Batista MA, Silveira DL, Martins-Filho OA. Hybrid polymeric companies of polycaprolactone and gelatine and process of obtaining. BR1020170283747, 2017.
[65]
Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157: 220-33.
[66]
Suzuki M, Kato C, Kato A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol 2015; 28: 133-9.
[67]
Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs 2018; 10: 183-203.
[68]
Gao Y. Monoclonal Antibodies and Its Application. CN107987163A, 2018.
[69]
Rankin EB, Giaccia AJ. The receptor tyrosine kinase AXL in cancer progression. Cancers 2016; 8: 103-18.
[70]
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1: 36-42.
[71]
Yang G, Yu C. Anti-cd19 fully human antibodies or antibody fragments, and methods and uses. CN107880128A, 2018.
[72]
Jung G, Grosse-Hovest L. Methods of using bispecific antibodes for treating b-cell-mediated autoimmune diseases or Auto-reactive B-cells. US9624310B2, 2017.
[73]
Grewal I, Khare S, Gresser M. Engineered antibodyinterferon fusion molecules for treatment of autoimmune diseases. US9783589B2, 2017.
[74]
Greenfield SA, Garcia-Rates S, Morril P. Antibodies against the T14 peptide of acetylcholinesterase. GB2541477A, 2017.
[75]
Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-17.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 3
Year: 2019
Page: [170 - 186]
Pages: 17
DOI: 10.2174/1872208313666190114150511
Price: $65

Article Metrics

PDF: 41
HTML: 7